TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
GNLX

Genelux Corporation

Healthcare · Biotechnology

2.40$ -3.4% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

All figures as a percentage of total assets in the same period.

Tick rows to compare them in a chart (up to 4)

Balance Sheet GNLX
Line item 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
16.8% 81.9% 71.6% 34.2% 86.8% 90.9% 79.5%
13.0% 81.0% 55.3% 7.2% 33.8% 24.7% 28.0%
13.0% 81.0% 55.3% 7.2% 83.1% 89.0% 76.7%
80.8% 17.5% 27.2% – – – –
856.2% 261.7% 507.5% 747.0% 30.2% 24.3% 39.3%
448.8% 103.5% 276.7% 571.8% 23.5% 19.9% 32.7%
140.4% 27.8% 80.7% 301.3% 2.3% 0.9% 2.2%
110.8% 6.6% 54.9% 122.5% 13.6% 16.0% 22.9%
– 154.9% 221.8% 154.1% – – –
-756.2% -161.7% -407.5% -647.0% 69.8% 75.7% 60.7%
-4,711.5% -1,200.9% -2,271.4% -3,431.3% -794.2% -724.1% -1,490.2%
719.8% 168.6% 290.6% 443.9% 87.6% 90.6% 195.4%

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?